| Item Type | Name |
|
Concept
|
Diabetes Mellitus, Type 1
|
|
Concept
|
Diabetes Mellitus, Type 2
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ?
|
|
Academic Article
|
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
|
|
Academic Article
|
Therapeutic challenges in the obese diabetic patient with hypertension.
|
|
Academic Article
|
Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance.
|
|
Academic Article
|
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
|
|
Academic Article
|
Renal mortality associated with non-insulin-dependent diabetes mellitus.
|
|
Academic Article
|
Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.
|
|
Academic Article
|
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.
|
|
Academic Article
|
Microalbuminuria: what is it? Why is it important? What should be done about it?
|
|
Academic Article
|
Antihypertensive therapy and the risk of type 2 diabetes mellitus.
|
|
Academic Article
|
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
|
|
Academic Article
|
Risks for renal involvement in diabetes.
|
|
Academic Article
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
|
Academic Article
|
Oral antidiabetic agents safe with renal disease?
|
|
Academic Article
|
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
|
|
Academic Article
|
The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
|
|
Academic Article
|
Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control.
|
|
Academic Article
|
Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches.
|
|
Academic Article
|
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
|
|
Academic Article
|
Hypertension and nephropathy.
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
What have we learned from the current trials?
|
|
Academic Article
|
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
|
|
Academic Article
|
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.
|
|
Academic Article
|
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
|
|
Academic Article
|
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
|
|
Academic Article
|
Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes.
|
|
Academic Article
|
Antihypertensive agents, insulin sensitivity, and new-onset diabetes.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
|
|
Academic Article
|
beta-blocker use and diabetes symptom score: results from the GEMINI study.
|
|
Academic Article
|
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus.
|
|
Academic Article
|
The ADVANCE trial: further PROGRESS with HOPE.
|
|
Academic Article
|
Risk factor assessment for new onset diabetes: literature review.
|
|
Academic Article
|
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
|
|
Academic Article
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
|
Academic Article
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
|
Academic Article
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
Effects of thiazolidinediones beyond glycaemic control.
|
|
Academic Article
|
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
|
|
Academic Article
|
Glycemic control and cardiovascular disease in chronic kidney disease.
|
|
Academic Article
|
Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
|
|
Academic Article
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
Lower blood pressure goals in high-risk cardiovascular patients: are they defensible?
|
|
Academic Article
|
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
|
|
Academic Article
|
Limitations of metformin use in patients with kidney disease: are they warranted?
|
|
Academic Article
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
|
Academic Article
|
Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes.
|
|
Academic Article
|
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
|
|
Academic Article
|
Mechanistic insights into diuretic-induced insulin resistance.
|
|
Academic Article
|
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers.
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
|
Academic Article
|
Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes.
|
|
Academic Article
|
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.
|
|
Academic Article
|
Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study.
|
|
Academic Article
|
Do fibrates truly preserve kidney function?
|
|
Academic Article
|
Telmisartan in incipient and overt diabetic renal disease.
|
|
Academic Article
|
Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents.
|
|
Academic Article
|
Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?
|
|
Academic Article
|
Hypertension in diabetic patients: an update of interventional studies to preserve renal function.
|
|
Academic Article
|
ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.
|
|
Academic Article
|
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
|
|
Academic Article
|
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
|
|
Academic Article
|
Body weight changes with beta-blocker use: results from GEMINI.
|
|
Academic Article
|
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.
|
|
Academic Article
|
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
|
|
Academic Article
|
Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival.
|
|
Academic Article
|
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
|
Academic Article
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
|
Academic Article
|
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
|
|
Academic Article
|
Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans.
|
|
Academic Article
|
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
|
|
Academic Article
|
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study.
|
|
Academic Article
|
Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective.
|
|
Academic Article
|
Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus".
|
|
Academic Article
|
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Microalbuminuria as a risk predictor in diabetes: the continuing saga.
|
|
Academic Article
|
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
|
|
Academic Article
|
Metformin nephrotoxicity insights: will they change clinical management?
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
|
Academic Article
|
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
|
|
Academic Article
|
Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted?
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
In search for the 'sweet spot' for blood pressure level in diabetes.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
|
|
Academic Article
|
Update on blood pressure goals in diabetes mellitus.
|
|
Academic Article
|
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
|
|
Academic Article
|
Hypertension: Impact of blood pressure lowering in type 2 diabetes.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.
|
|
Academic Article
|
Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
|
|
Academic Article
|
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
|
|
Academic Article
|
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
|
|
Academic Article
|
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
|
|
Academic Article
|
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
|
|
Academic Article
|
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
|
|
Academic Article
|
Diabetes: Blood pressure goals in T2DM - time for a rethink?
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
|
|
Academic Article
|
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
|
|
Academic Article
|
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
|
|
Academic Article
|
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
|
|
Academic Article
|
Baseline characteristics and enrichment results from the SONAR trial.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
|
|
Academic Article
|
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.
|
|
Academic Article
|
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
|
|
Academic Article
|
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Blood Pressure Control and Cardiovascular/Renal Outcomes.
|
|
Academic Article
|
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.
|
|
Academic Article
|
SGLT2 Inhibitors and Mechanisms of Hypertension.
|
|
Academic Article
|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
|
|
Academic Article
|
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes.
|
|
Academic Article
|
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
|
|
Academic Article
|
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not.
|
|
Academic Article
|
Creatinine Bump Following Antihypertensive Therapy.
|
|
Academic Article
|
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
|
|
Academic Article
|
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
|
|
Academic Article
|
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
|
|
Academic Article
|
Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
|
|
Academic Article
|
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
|
|
Academic Article
|
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?
|
|
Academic Article
|
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
|
|
Academic Article
|
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
|
|
Academic Article
|
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
|
|
Academic Article
|
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
|
|
Academic Article
|
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
|
|
Academic Article
|
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
|
|
Academic Article
|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial.
|
|
Academic Article
|
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply.
|
|
Academic Article
|
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
|
|
Academic Article
|
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
|
|
Academic Article
|
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
|
|
Academic Article
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
|
|
Academic Article
|
Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes".
|
|
Academic Article
|
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
|
|
Academic Article
|
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
|
|
Academic Article
|
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial.
|
|
Academic Article
|
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
|
|
Academic Article
|
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
|
|
Academic Article
|
3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022.
|
|
Academic Article
|
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022.
|
|
Academic Article
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
|
Academic Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
|
|
Academic Article
|
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
|
|
Academic Article
|
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
|
|
Academic Article
|
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
|
|
Academic Article
|
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
|
|
Academic Article
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
|
Academic Article
|
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
|
|
Academic Article
|
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone.
|
|
Academic Article
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
|
Academic Article
|
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.
|
|
Academic Article
|
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
|
|
Academic Article
|
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.
|
|
Academic Article
|
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
|
|
Academic Article
|
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
|
|
Academic Article
|
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
|
|
Academic Article
|
Editorial Cycles and Continuity of Diabetes Care.
|
|
Academic Article
|
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease.
|
|
Academic Article
|
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
|
|
Academic Article
|
Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
|
Academic Article
|
Glucose-lowering treatment patterns in patients with diabetic kidney disease.
|
|
Academic Article
|
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
|
|
Academic Article
|
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR).
|
|
Academic Article
|
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
|
|
Academic Article
|
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
|
|
Academic Article
|
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial.
|
|
Academic Article
|
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
|
|
Academic Article
|
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
The changing trajectory of diabetic kidney disease.
|
|
Academic Article
|
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
|
|
Academic Article
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
|
Academic Article
|
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
|
|
Academic Article
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
|
|
Academic Article
|
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
|
|
Academic Article
|
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
|
|
Academic Article
|
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
|
|
Academic Article
|
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
|
|
Academic Article
|
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
|
|
Academic Article
|
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
|
|
Academic Article
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
|
Academic Article
|
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.
|
|
Academic Article
|
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.
|
|
Academic Article
|
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
|
|
Academic Article
|
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
|
|
Academic Article
|
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|
|
Academic Article
|
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
|
|
Academic Article
|
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
|
|
Academic Article
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|
|
Academic Article
|
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
|